Business The science behind a fond farewell Published 3 years ago on 7 October 2021 By Terry Power Share Tweet Between the high cost and testing hurdles, molnupiravir may not be the “game changer” against COVID. Read More Related Topics:biogen aduhelmcoronavirusCOVIDcovid treatment costsdigital healthfarewellfondfortune the capsuleGE Healthcaremonoclonal antibodiessciencethe capsulethe science of a farewell Up Next The DOJ wants you to admit your cybersecurity problem Don't Miss Who beat out Tiger Global as the most active venture investor of the third quarter? Continue Reading You may like Decoding the data of the Chinese mpox outbreak China is suddenly dealing with another public health crisis: mpox Covid hasn’t entirely gone away—here’s where we stand The Download: how AI is changing science, and limits on White House contact with tech firms Eric Schmidt: This is how AI will transform how science gets done Did US Help Fund Coronavirus Research In Controversial Wuhan Lab? Business These fast-growing Sun Belt cities suffer from high inflation Published 3 years ago on 4 May 2022 By Terry Power U.S. migration hotspots tend to have the highest inflation | Fortune You need to enable JavaScript to view this site. Continue Reading Business The U.S. is seizing a $325 million helipad-equipped megayacht in Fiji. The question is which Russian oligarch it belongs to Published 3 years ago on 4 May 2022 By Terry Power Oligarch sanctions: U.S. seizing $325 million megayacht in Fiji. The question is which Russian billionaire it belongs to | Fortune You need to enable JavaScript to view this site. Continue Reading Business Investors bank on today’s ‘once-in-a-generation’ Fed hike to be one of several Published 3 years ago on 4 May 2022 By Terry Power Fed rate hike: decision day rattles markets as investors worry that a giant ‘once-in-a-generation’ hike will be one of several this year | Fortune You need to enable JavaScript to view this site. Continue Reading